Viatris Reports Q3 2026 Results with Raised Full-Year Guidance Amid Supply Constraints
Viatris (VTRS) reported third-quarter revenues of $3.75 billion, remaining flat year-over-year on an operational basis. Despite a $100 million revenue headwind caused by manufacturing remediation at its Nashik facility—which led to a voluntary suspension of operations in October—the company achieved adjusted EPS of $0.71, a 3% operational increase. Growth was driven primarily by North American net sales, which rose 7% due to high demand for estradiol patches and new injectable launches. Looking ahead, management raised its full-year guidance across several key metrics, including revenue ($14.7B–$14.9B), adjusted EBITDA, and adjusted EPS. The company is also progressing with the $1.65 billion acquisition of Pacira, targeting $50 million in annual synergies by 2028. While supply disruptions are expected to impact fourth-quarter revenues by approximately $100 million, the company maintains a stable gross leverage ratio of 2.9x.
Tickers: $VTRS
Topics: eps fda regulation guidance revenue supply chain